证券代码：300896 证券简称：爱美客 公告编号：2023-035号 爱美客技术发展股份有限公司 第三届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 爱美客技术发展股份有限公司（以下简称"公司"）第三届董事会第七次会 议于2023年8月24日在公司会议室以现场与通讯表决相结合的方式召开。本次会议 应到董事9人，实到董事9人。会议通知已于2023年8月14日通过邮件和电话的方式 送达各位董事。 本次会议的召开符合《中华人民共和国公司法》《公司章程》以及有关法律、 法规的规定。会议由公司董事长简军主持，监事和高级管理人员列席了会议。 二、董事会会议审议情况 与会董事对本次会议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于<公司2023年半年度报告>及<摘要>的议案》 1 216,330,035股为基数，向全体股东每10股派发现金股利18.48元（含税）。预计 合计派发现金股利39,977.79万元（含税），占2023年上半年度公司合并报表归属 于母公司所有者净利润的41.5%。本次不送红股，不 ...

证券代码：300896 证券简称：爱美客 公告编号：2023-036 号 爱美客技术发展股份有限公司 一、监事会会议召开情况 爱美客技术发展股份有限公司（以下简称"公司"）第三届监事会第五次会 议于 2023 年 8 月 24 日在公司会议室以现场与通讯表决相结合的方式召开。会议 通知已于 2023 年 8 月 14 日通过邮件和电话的方式送达各位监事。本次会议应到 监事 3 人，实到监事 3 人。本次会议的召开符合《中华人民共和国公司法》《公 司章程》以及有关法律、法规的规定。会议由公司监事会主席陈重主持。 二、监事会会议审议情况 与会监事对本次会议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于<公司 2023 年半年度报告>及<摘要>的议案》 监事会专项审核意见：经审核，监事会认为：公司编制和审核 2023 年半年 度报告的程序符合法律、行政法规、中国证监会和深圳证券交易所的规定，报告 内容真实、准确、完整的反映了上市公司的实际情况，不存在任何虚假记载、误 导性陈述或者重大遗漏。 具体内容详见公司同日刊登于巨潮资讯网（www.cninfo.com.cn）的《2023 年半年度报告》及《2 ...

| 业 | | 艾诺克医美科技（长沙）有限公司 | 其他关联方 | 预付账款 | | 495.20 | | 495.20 采购商品 | 经营性往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 北京九州通医药有限公司 | 其他关联方 | 预付账款 | 0.08 | | 0.08 | 采购商品 | 经营性往来 | | | 总计 | - | - | - | 3,044.88 | 5,497.41 | 354.88 | 8,187.41 | - | 法定代表人：简军 主管会计工作负责人：张仁朝 会计机构负责人：王静 上市公司 2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：爱美客技术发展股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市 公司的关联关 | 上市公司核算的会 | 2023 年期 初占用资 | 2023 年半年度占用 累计发生金额（不含 | 2023 年半年度占 用资金的利息（如 | 2023 年半年度偿 | | 2023 | 年期末占用 占用形成原 ...

FEREBARRRBGEIRAF 2023 SEH —F AR IEFAHY: 300896 IFAFR: BEK NSRS 2023-023 5 RRBUARR BB ARAF 2023 FE—FHERE AN T R R PRI SRR A A e S, SRR ROCER. iR 1 R BRI - HEARIR: Ldegie, R RS, W9 WO R R IR RS 1, HER, 58, AP FEREARACER R P IERRR BRI IR, IF AR BRI 7 (KA DA R BRI & M RREHARRBRBEIRAF 2023 FEE—FRER — EEMEHE (=) EHEKWBERMY 5T ) T T G TS D P v B OfF BIER R S e D& BURARE DRt EMEE O T el @3bERE 630, 121, 089. 65 430, 712, 581. 75 430, 712, 581. 75 414, 065, 833. 05 280, 095, 605. 38 273,902, 632. 86 387, 087, 745. 9 ...

爱美客技术发展股份有限公司 投资者关系活动记录表 应用领域的更多市场机会。公司在产品引进、对外合作方面有成熟的运 作机制。感谢您的关注。 爱美客技术发展股份有限公司 投资者关系活动记录表 编号：2023-001 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （投资者交流会） 参与单位名称 及人员姓名 通过全景网"投资者关系互动平台"(http://ir.p5w.net)参与 2022 年 度网上业绩说明会的投资者 时 间 2023 年 3 月 28 日 15:00-17:00 地 点 "全景•投资者关系互动平台"(http://ir.p5w.net) 上市公司接待 人员姓名 董事长：简军 总经理：石毅峰 董事会秘书：简勇 财务总监：张仁朝 独立董事：陈刚 保荐代表人：洪立斌 投资者关系活 动主要内容介 绍 1、司美格鲁肽在效果、副作用和使用方式上要先进于利拉鲁肽；重 组胶原蛋白各方面性能要优于动物胶原蛋白（公司收购的沛奇隆是动物 胶原蛋白），想问问您，公司的利拉鲁肽和收购的动物胶原蛋白这两款 产品未来的市场前景如何保障？未来公司在收 ...

Dividend Distribution - The company plans to distribute a cash dividend of 28 RMB per 10 shares to all shareholders, based on a total of 216,360,000 shares[3]. - A cash dividend of CNY 28 per 10 shares was proposed, totaling CNY 605.81 million, which represents 47.94% of the net profit attributable to shareholders[149]. - The total cash dividend amount accounted for 100% of the total distributable profit[148]. Financial Performance - The company's operating revenue for 2022 was ¥1,938,838,363.70, representing a 33.91% increase compared to the previous year[12]. - The net profit attributable to shareholders for 2022 was ¥1,263,558,415.71, reflecting a growth of 31.90% year-over-year[12]. - The net profit after deducting non-recurring gains and losses was ¥1,197,352,350.70, which is a 30.92% increase from the previous year[12]. - The net cash flow from operating activities reached ¥1,193,935,203.61, marking a 26.64% increase compared to 2021[12]. - The total assets at the end of 2022 amounted to ¥6,258,547,700.17, an 18.71% increase from the end of 2021[12]. - The net assets attributable to shareholders at the end of 2022 were ¥5,846,126,232.19, showing a 16.24% increase year-over-year[12]. - The company reported a basic and diluted earnings per share of ¥5.84, which is a 31.83% increase from the previous year[12]. Market Position and Growth - The company holds a 21.3% market share in the domestic market for sodium hyaluronate-based dermal fillers, ranking first among domestic manufacturers[21]. - The medical beauty market in China has a compound annual growth rate (CAGR) of 17.5% from 2017 to 2021, significantly outpacing the global market[20]. - The company anticipates continued high growth potential in the medical beauty market, as China's penetration rate remains significantly lower than that of mature markets[20]. - The company has observed a trend of domestic products replacing imported products in the medical beauty industry, leading to an increase in market share for local manufacturers[20]. Research and Development - Research and development investment accounted for 8.93% of total revenue, with a year-on-year increase of 69.20% in R&D spending[26]. - The company has accumulated 49 patents, with 25 being invention patents, and 25.39% of its total workforce engaged in R&D[27]. - The company is currently conducting clinical trials for several innovative products, including a gel for correcting chin retrusion and a type A botulinum toxin for improving glabellar lines[26]. - The company has successfully commercialized a series of dermal fillers based on sodium hyaluronate and polylactic acid, as well as facial implant lines[23]. Strategic Initiatives - The company’s future strategies include market expansion and potential mergers and acquisitions, although specific details are not disclosed[3]. - The company has strengthened its strategic layout in weight management and fat reduction, with a focus on the deoxycholic acid injection project and a collaboration with Beijing Zhitai Biopharmaceutical Technology Co., Ltd. for the semaglutide injection project, which is currently in preclinical research[27]. - The company has become the exclusive distributor of HUTOX botulinum toxin in China, enhancing its product pipeline and competitive strength in the botulinum toxin category[27]. Corporate Governance - The company’s governance structure complies with relevant laws and regulations, ensuring independent operation without interference from controlling shareholders[114]. - The company has established a transparent performance evaluation and incentive mechanism, with a dedicated remuneration and assessment committee[112]. - The company has a complete and independent production and operational system, with no instances of asset guarantees or resource occupation by controlling shareholders reported during the reporting period[114]. Environmental Responsibility - The company installed a new wastewater treatment system in April 2022, significantly reducing water pollutant emissions[158]. - Air pollution control measures include organized emissions and regular inspections, ensuring compliance with national and local environmental standards[158]. - The company is committed to ongoing environmental education and training for employees, with two sessions held in 2022[159]. Employee Development - The company conducted 4 new employee training sessions covering 340 individuals, with an average course quality evaluation score of 4.8[145]. - The employee coverage rate for training programs reached 65%, with a total of 8,346 learning instances recorded[145]. - The company has established a flexible salary system linked to performance, ensuring employee interests are protected[143]. Future Outlook - The company provided guidance for 2023, projecting a revenue growth of 20% to reach approximately 1.8 billion RMB[125]. - The company plans to enhance R&D investment in 2023, focusing on biomedical materials and expanding into biomedicine, aiming to strengthen its technological leadership and enrich its product line[101]. - The management emphasized a commitment to sustainability, aiming for a 50% reduction in carbon emissions by 2025[125].

证券代码：300896 证券简称：爱美客 公告编号：2023-013 号 爱美客技术发展股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为充分尊重投资者、提升公司与投资者之间的交流效率及针对性，现就公司 2022 年度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议。公司欢迎广大投资者于 2023 年 3 月 27 日（星期一）15:00 前，将关注的问 题通过 http://ir.p5w.net/zj 界面的提问通道进行提问，或扫描下方二维码， 进入问题征集专题页面提问。 1 公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进行回答。 敬请广大投资者积极参与！ 爱美客技术发展股份有限公司（以下简称"公司"）《2022 年年度报告全 文》及《2022 年年度报告摘要》已于 2023 年 3 月 9 日在中国证监会指定的创业 板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）上披露。 为便于广大投资者更深入、全面的了解公司情况，公司定于 2023 年 3 ...